Results of the SUSTAIN-6 trial (ClinicalTrials.gov Identifier: NCT01720446) published in 2016 were among the first to suggest that there may be microvascular complications associated with GLP-1 RA use ...

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

She began using Wegovy, the version of Ozempic approved for weight loss, after struggling with obesity. She reveals which ...

Understanding the GLP-1 consumer. Getting to know GLP-1 consumers is becoming a high priority for the food and beverage industry, as their numbers rise and buying power grows. Now a new report from ...

Over three years of follow-up between 2020 and 2023, 0.2% (93 patients) of those in the GLP-1 user group were diagnosed with nAMD, as were 0.1% (88 patients) in the contrasting group.

Data were included for 85,015 adults with a body mass index ≥30 kg/m 2 and a diagnosis of diabetes who newly initiated a GLP-1 RA or DPP-4 inhibitor between 2013 and 2023.

GLP-1 medications have demonstrated benefits beyond weight loss, including reducing the risk of heart disease and slowing the progression of kidney disease in certain populations.

GLP-1 receptor agonist users had a significant 39% higher risk of requiring KRT (95% CI, 1.19-1.63) compared with SGLT2 inhibitor users, Dr Chang’s team reported in the American Journal of ...

People taking such GLP-1 drugs lost just under 9% of their body weight on average after a year, researchers reported June 10 in the journal Obesity.. That’s far less than the 15% to 21% body ...

GLP-1 weight-loss drugs such as Wegovy and Zepbound have taken the health care world by storm, with hundreds of thousands of people turning to the medications for their pound-shedding properties.